[Membre-smv] RE : Interference Fièvre jaune et ROR

Jeu 16 Juin 11:17:53 CEST 2011

bonjour,

Merci de cette information importante et intéressante. En effet on est souvent amené à faire ces 2 vaccins le même jour, dès 9 mois, pour les nourrissons qui partent au pays.

Souvent on n'a pas le temps de mettre 30 jours entre les 2 vaccins.

Dans ces cas là , peut-être faudrait-il mieux faire seulement Rouvax et ROR, les 2 autres valences n'ayant pas d'intéret et fortement touchées par l'interférence.

On verra dans l'article in extenso quelles sont les recommandations au Brésil, qui jusqu'en 2010, ne notifiait pas de résurgence de la rougeole (68 cas déclarés).

bien cordialement

Dr Sabine BARON

CHRU de TOURS

02 47 47 82 49

________________________________
De : membre-smv-bounces at medecine-voyages.fr [membre-smv-bounces at medecine-voyages.fr] de la part de julian cornaglia [julinaglia at hotmail.com]
Date d'envoi : jeudi 9 juin 2011 15:30
À : membre-smv at medecine-voyages.fr
Objet : [Membre-smv] Interference Fièvre jaune et ROR

Bonjour a tous,
Je savais qu'il avait un étude français "Vaccin FJ et ROR" en cours (ou déjà fini ?)...
Un article va aparaître en "Vaccine" (Article en Press).
Des commentaires ?
Dr Julian CORNAGLIA
SMIT-CH Perpignan

Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella
<http://www.sciencedirect.com/science?_ob=ShoppingCartURL&_method=add&_udi=B6TD4-530RP90-2&_acct=C000050221&_version=1&_userid=10&_ts=1307623625&md5=1cdb27b4230c21e2bdfb0fae183a3b95>

Juliana Romualdo Nascimento Silvaa<http://www.sciencedirect.com/science/article/pii/S0264410X11007298#aff0005>, [E-mail The Corresponding Author] <mailto:julianarns at gmail.com> , Luiz Antonio B. Camachoa<http://www.sciencedirect.com/science/article/pii/S0264410X11007298#aff0005>, [Corresponding Author Contact Information] <http://www.sciencedirect.com/science/article/pii/S0264410X11007298#cor0005> , [E-mail The Corresponding Author] <mailto:luiz.camacho at ensp.fiocruz.br> , [E-mail The Corresponding Author] <mailto:luiz.camacho at pq.cnpq.br> , Marilda M. Siqueirab<http://www.sciencedirect.com/science/article/pii/S0264410X11007298#aff0010>, [E-mail The Corresponding Author] <mailto:mmsiq at ioc.fiocruz.br> , Marcos da Silva Freirec<http://www.sciencedirect.com/science/article/pii/S0264410X11007298#aff0015>, [E-mail The Corresponding Author] <mailto:freire at bio.fiocruz.br> , Yvone P. Castrod<http://www.sciencedirect.com/science/article/pii/S0264410X11007298#aff0020>, [E-mail The Corresponding Author] <mailto:ivone.p at brturbo.com.br> , Maria de Lourdes S. Maiae<http://www.sciencedirect.com/science/article/pii/S0264410X11007298#aff0025>, [E-mail The Corresponding Author] <mailto:lourdes.maia at bio.fiocruz.br> , Anna Maya Y. Yamamuraf<http://www.sciencedirect.com/science/article/pii/S0264410X11007298#aff0030>, [E-mail The Corresponding Author] <mailto:anna at bio.fiocruz.br> , Reinaldo M. Martinsg<http://www.sciencedirect.com/science/article/pii/S0264410X11007298#aff0035>, [E-mail The Corresponding Author] <mailto:Rmenezes at bio.fiocruz.br> , Maria da Luz F. Lealh<http://www.sciencedirect.com/science/article/pii/S0264410X11007298#aff0040>, [E-mail The Corresponding Author] <mailto:Malu at bio.fiocruz.br>  and Collaborative Group for the Study of Yellow Fever Vaccines1<http://www.sciencedirect.com/science/article/pii/S0264410X11007298#fn0005>
a Departamento de Epidemiologia, Escola Nacional de Saúde Pública, FIOCRUZ, Rua Leopoldo Bulhões, 1480, sala 820, Manguinhos, Rio de Janeiro 21041-210, RJ, Brazil
b Laboratório de Vírus Respiratórios e do Sarampo (LVRS), Instituto Oswaldo Cruz, FIOCRUZ, Pavilhão Helio e Peggy Pereira, sala B105, Rua Leopoldo Bulhões 1480, Manguinhos, Rio de Janeiro 21041-210, RJ, Brazil
c Vice-Diretoria de Desenvolvimento Tecnológico de Bio-Manguinhos, FIOCRUZ, Av. Brasil, 4365 – Manguinhos, Rio de Janeiro 21040-360, RJ, Brazil
d Programa de Imunizações da Secretaria Distrital de Saúde, SGAP, Lote 6, Bloco G, Parque de Apoio, SIA, Brasilia 71-410-010, DF, Brazil
e Assessoria Clínica, Bio-Manguinhos, FIOCRUZ, Av. Brasil, 4365 – Manguinhos, Rio de Janeiro 21040-360, RJ, Brazil
f Laboratorio de Tecnologia Virológica, Bio-Manguinhos, FIOCRUZ, Av. Brasil, 4365 – Pavilhão Rocha Lima, Manguinhos, Rio de Janeiro 21040-360, RJ, Brazil
g Consultor Científico, Bio-Manguinhos, FIOCRUZ, Av. Brasil, 4365 – Manguinhos, Rio de Janeiro 21040-360, RJ, Brazil
h Vice-Diretoria de Qualidade de Bio-Manguinhos, FIOCRUZ, Av. Brasil, 4365 – Manguinhos, Rio de Janeiro 21040-360, RJ, Brazil
Received 21 November 2010;
revised 5 May 2011;
accepted 9 May 2011.
Available online 2 June 2011.

Abstract
A randomized trial was conducted to assess the immunogenicity and reactogenicity of yellow fever vaccines (YFV) given either simultaneously in separate injections, or 30 days or more after a combined measles–rubella–mumps (MRM) vaccine. Volunteers were also randomized to YFV produced from 17DD and WHO-17D-213 substrains. The study group comprised 1769 healthy 12-month-old children brought to health care centers in Brasilia for routine vaccination. The reactogenicity was of the type and frequency expected for the vaccines and no severe adverse event was associated to either vaccine. Seroconversion and seropositivity 30 days or more after vaccination against yellow fever was similar across groups defined by YFV substrain. Subjects injected YFV and MMR simultaneously had lower seroconversion rates – 90% for rubella, 70% for yellow fever and 61% for mumps – compared with those vaccinated 30 days apart – 97% for rubella, 87% for yellow fever and 71% for mumps. Seroconversion rates for measles were higher than 98% in both comparison groups. Geometric mean titers for rubella and for yellow fever were approximately three times higher among those who got the vaccines 30 days apart. For measles and mumps antibodies GMTs were similar across groups. MMR's interference in immune response of YFV and YFV's interference in immune response of rubella and mumps components of MMR had never been reported before but are consistent with previous observations from other live vaccines. These results may affect the recommendations regarding primary vaccination with yellow fever vaccine and MMR.

-------------- section suivante --------------
Une pièce jointe HTML a été nettoyée...
URL: <http://colossus02.mailclub.fr/pipermail/membre-smv/attachments/20110616/dc0fa0c2/attachment.html>
-------------- section suivante --------------
Une pièce jointe autre que texte a été nettoyée...
Nom: REemail.gif
Type: image/gif
Taille: 320 octets
Desc: REemail.gif
URL: <http://colossus02.mailclub.fr/pipermail/membre-smv/attachments/20110616/dc0fa0c2/attachment-0004.gif>
-------------- section suivante --------------
Une pièce jointe autre que texte a été nettoyée...
Nom: REcor.gif
Type: image/gif
Taille: 203 octets
Desc: REcor.gif
URL: <http://colossus02.mailclub.fr/pipermail/membre-smv/attachments/20110616/dc0fa0c2/attachment-0005.gif>